Development and assessment of a new cage-like particle adjuvant

BERTONA, D.; PUJATO, N; BONTEMPI, I.; GONZALEZ, V.D.G.; CABRERA, G.; GUGLIOTTA, L.M.; HOZBOR, D.; NICASTRO, A.; CLAVINHO, L.; MARCIPAR, I.S.

JOURNAL OF PHARMACY AND PHARMACOLOGY

PHARMACEUTICAL PRESS-ROYAL PHARMACEUTICAL SOC GREAT BRITIAN

Año: 2017 vol. 69 p. 1293 - 1303

0022-3573

Objectives To obtain and assess stable cage-like particles with low surface chargedensity, which can be prepared using a standardized, economic and scalablemethod.Methods To form these nanoparticles, the lipid composition and proportion aswell the method were modified in relation to cage-like particles previouslydescribed elsewhere. Bovine albumin was used to compare ISPA performancewith that of other adjuvants in mice and to assess stability. Adjuvant efficacy wasanalysed using a mouse model of Trypanosoma cruzi infection, which shows protectionagainst an intracellular infection that needs a strong cellular response.Key findings The new particles were better in terms of level, kinetics and profileof humoral responses than Freund Adjuvant, aluminium hydroxide and MontanideTM ISA 206; they also tended to improve ISCOMATRIX? performance.Particle size and adjuvant performance were conserved during the 6-month periodassessed after preparation. In the model of Trypanosoma cruzi infection, miceimmunized with ISPA and trans-sialidase developed high protection.Conclusions The obtained nanoparticles were stable and outperformed the otherassessed adjuvants in joining together the capacity of most adjuvants to enhancethe immune response against specific antigen, to reduce the number of doses, tohomogenize the response between individuals and to reach a balanced TH1/TH2response.